Stockscreener 앱 받기
11.91
0.58%
-0.07
시간 외 거래:
12.10
0.19
+1.60%
전일 마감가:
$11.98
열려 있는:
$12.01
하루 거래량:
396.22K
Relative Volume:
0.89
시가총액:
$323.01M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
-10.27
EPS:
-1.16
순현금흐름:
$-21.00M
1주 성능:
-3.17%
1개월 성능:
-13.70%
6개월 성능:
-26.44%
1년 성능:
-36.62%
1일 변동 폭
$11.43
$12.15
1주일 범위
$11.43
$12.55
52주 변동 폭
$8.04
$25.88
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
ARCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
11.91 | 331.14M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment - MSN
Arcturus Therapeutics Holdings Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 Earnings - GuruFocus
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
Is Arcturus Therapeutics Holdings Inc. stock overvalued or undervaluedHigh-yield portfolio picks - Jammu Links News
What is the risk reward ratio of investing in Arcturus Therapeutics Holdings Inc. stockRapid return acceleration - Jammu Links News
How does Arcturus Therapeutics Holdings Inc. compare to its industry peersFree Risk Assessment Services - Jammu Links News
What are analysts’ price targets for Arcturus Therapeutics Holdings Inc. in the next 12 monthsBuild a winning investment portfolio - Jammu Links News
When is Arcturus Therapeutics Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
Is Arcturus Therapeutics Holdings Inc. a growth stock or a value stockGet professional guidance for market timing - Jammu Links News
What catalysts could drive Arcturus Therapeutics Holdings Inc. stock higher in 2025Get alerts on high-potential stock breakouts - Jammu Links News
What drives Arcturus Therapeutics Holdings Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What is Arcturus Therapeutics Holdings Inc. company’s growth strategyTremendous financial leverage - Jammu Links News
What are Arcturus Therapeutics Holdings Inc. company’s key revenue driversRapid return acceleration - Jammu Links News
Arcturus Therapeutics Holdings Inc expected to post a loss of 90 cents a shareEarnings Preview - TradingView
Investors Don't See Light At End Of Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Tunnel - 富途牛牛
High Growth US Tech Stocks To Watch In August 2025 - simplywall.st
Can Arcturus Therapeutics Holdings Inc. hit a new high this monthWeekly Stock Opportunity Radar Scanner Activated - metal.it
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load? - simplywall.st
Why is Arcturus Therapeutics Holdings Inc. stock attracting strong analyst attentionBeginner Investor Report With Low Risk - Jammu Links News
Arcturus Therapeutics Holdings Inc. Sees Relief Buying After Extended DropValue Investing Picks With Stability Outlined - beatles.ru
Published on: 2025-07-29 23:05:26 - metal.it
Sector ETF Data Correlates with Strength in Arcturus Therapeutics Holdings Inc.Investment Playbook for Growing Markets Shared - metal.it
Using R and stats models for Arcturus Therapeutics Holdings Inc. forecastingFree Real-Time Analysis With Entry Targets - Newser
Price Floor Holding on Arcturus Therapeutics Holdings Inc. — Rebound PossibleSmart Investment Tips Gaining Popularity Among Analysts - metal.it
How Arcturus Therapeutics Holdings Inc. stock performs during market volatilityCapital Growth Summary Over Five Years - Newser
Arcturus Therapeutics Holdings Inc. Shows Risk Reward Favoring UpsideGrowth Focused Entry Plan Suggestions Issued - metal.it
Does Arcturus Therapeutics Holdings Inc. stock perform well during market downturnsFree Stock Market Real-Time Monitoring - Jammu Links News
Why Arcturus Therapeutics Holdings Inc. stock attracts strong analyst attentionTrading Volume Anomaly Summary and Insight - Newser
New York State Common Retirement Fund Sells 1,100 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
What makes Arcturus Therapeutics Holdings Inc. stock price move sharplyBuild wealth steadily with proven strategies - Jammu Links News
Arcturus Therapeutics Holdings Inc. Stock Support and Resistance Levels You Should KnowFree Stock Market Swing Trading Strategies - metal.it
Is Arcturus Therapeutics Holdings Inc. Stock Overbought or Oversold RSI Indicator AnalysisMinimized Risk Maximum Return - Newser
What institutional investors are buying Arcturus Therapeutics Holdings Inc. stockInvest confidently with data-driven strategies - Jammu Links News
Is Arcturus Therapeutics Holdings Inc. a good long term investmentFree Investment Community - PrintWeekIndia
Does Arcturus Therapeutics Holdings Inc. stock pay reliable dividendsOutstanding capital returns - jammulinksnews.com
What analysts say about Arcturus Therapeutics Holdings Inc. stockExceptional trading performance - PrintWeekIndia
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):